Acyclovir USP 5% w/w
Methyl Hydroxybenzoate BP 0.06% w/w, Propyl Hydroxybenzoate BP 0.03% w/w
Non-greasy white cream.
Acyclovir is active against herpes simplex virus type 1 and type 2 and
against varicella zoster virus. This activity is due to intracellular
conversion of acyclovir by a viral thymidine kinase to the monophosphate
with subsequent conversion to the diphosphate and active triphosphate. This
active form inhibits the herpes virus DNA polymerise enzyme as well as being
incorporated into viral DNA. This process is highly selective for infected
cells. Studies in animals and in vitro show various sensitivities but
demonstrate that these viruses are inhibited by concentrations of acyclovir
that are readily achieved clinically. Herpes simplex virus type 1 appear to
be the most susceptible, than type 2, followed by varicella zoster virus.
Herpes simplex virus infections of the skin including initial and recurrent
genital herpes and herpes labialis.
Apply to lesions or impending lesions 5 times daily at 4-hourly intervals
omitting the night-time dose. Treatment should start as early as possible
after the start of an infection. For recurrent episodes, it is important to
start treatment during the prodromal period or when the lesions first
appear. Continue treatment for 5 days. Treatment may be continued for up to
10 days if healing has not occurred.
Transient burning or stinging, mild drying and flaking of skin, erythema and
Not to be applied to mucous membranes, such as mouth, eye or vagina.
USE IN PREGNANCY
Should be used only if potential benefits outweigh the risks.
Contraindicated in patients known to be hypersensitive to acyclovir.
There is no reported drug interaction with topical acyclovir. Drug affecting
renal physiology could influence the pharmacokinetics of systemically
2g & l0g in aluminium tube
Store below 25°C